Team
Katja Stout, MBiochem (Oxon), MBA
Founder and Managing Partner
London
Katja is a communications strategist and entrepreneur with more than 25 years of international experience in life sciences and pharmaceuticals. She founded Scius Communications and previously co-founded Northbank Communications, which she helped build through to its sale to College Hill, now Instinctif Partners.
Through Scius, Katja works directly with CEOs to strengthen their corporate story, communicate the value of their science and build visibility with investors and potential partners. The consultancy has developed lasting relationships with international life sciences companies including Anocca, BC Platforms, Epitopea, Microbiotica and TILT Biotherapeutics, supporting financings, business development deals and other key milestones. In 2021, Katja supported communications for Vaccitech’s $160 million Series B financing and subsequent $150 million Nasdaq IPO.
Katja spent four years at AstraZeneca, initially as Director of Partnering Communications within the business development team, before becoming Vice President of Corporate Affairs for Global Product and Portfolio Strategy (GPPS). As a member of the GPPS leadership team, she led communications for AstraZeneca’s global product brands and the internal launch of the new GPPS function.
Before co-founding Northbank, Katja held in-house roles at SV Life Sciences, International Biotechnology Trust and Merlin Biosciences. She also worked at life sciences investor relations firm Russell-Welsh, now GCI Healthcare, in San Francisco. Earlier in her career, she was Head of Communications and Investor Relations at Genset SA, a Paris-based pioneer in personalised healthcare listed on Nasdaq and the Nouveau Marché.
Katja holds a master’s degree in Biochemistry from the University of Oxford and an MBA from Imperial College London.
